Please login to the form below

Not currently logged in
Email:
Password:

Immutep

This page shows the latest Immutep news and features for those working in and with pharma, biotech and healthcare.

Immutep slumps on latest efti data in breast cancer

Immutep slumps on latest efti data in breast cancer

Analyst Dr Chris Redhead at Goetzpartners said the outcomes was a “substantial setback” for Immutep, but doesn’t mean that efti is dead. ... Immutep will need to keep its foot on the gas if it hopes to keep pace with some larger, deep-pocketed

Latest news

  • Immutep spikes on trial of its LAG-3 drug with Keytruda Immutep spikes on trial of its LAG-3 drug with Keytruda

    Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... Immutep also has a phase 2b trial of efti ongoing

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...